Abiomed recalls Impella heart-pump controllers in Class I action over sensor

Abiomed is recalling the console that runs its Impella heart pumps, one of the most closely watched devices in critical cardiac care. The Food and Drug Administration recorded the action in its enforcement database on 23 September 2026 and classified it as Class I — the agency's most serious recall category, used where a defect could cause serious injury or death [s1]. The product named is the Automated Impella Controller, or AIC, the bedside unit that drives and monitors the pump [s1].

What is affected

The recall covers 5,232 units — 3,733 in the United States and 1,499 outside it — distributed nationwide and across a long list of international markets including the United Kingdom, Germany, Japan, Canada and Australia [s1]. The affected controllers span the regional product codes Abiomed assigns to the console, from 0042-0000-US for the United States to versions for Europe, the United Kingdom, Canada, Japan and India [s1]. Abiomed, based in Danvers, Massachusetts, began the recall itself on 12 August 2026, making this a voluntary, firm-initiated action [s1].

Why the purge system matters

The fault sits in the controller's pressure sensing. The record describes "the potential for purge cassette recognition issues due to the failure of the purge flag component of the purge pressure sensor assembly" [s1]. The purge system is not an accessory detail on an Impella pump: it pushes a dextrose-based fluid through the device to keep blood from entering and clotting in the motor. The controller has to recognise the purge cassette and track its pressure to manage that flow. A sensor assembly that fails to flag the cassette correctly undermines the console's ability to confirm the purge is running as intended.

An Impella is used in some of the sickest cardiac patients — people in cardiogenic shock or undergoing high-risk procedures, where the pump is temporarily doing work the heart cannot. In that setting the equipment is life-supporting, and a controller problem is treated with the seriousness the agency's top classification reflects. The enforcement record documents the nature of the defect and the number of units involved; it does not report patient outcomes, and the absence of such a report is not the same as proof that none occurred [s1].

The wider context

The Impella platform has been on the US market for years; the Impella Controller itself was cleared under 510(k) K093801 on 8 July 2010, part of a family of clearances covering the pumps, catheters and the console that runs them [s2]. A recall of the controller rather than the pump is a reminder that a device system is only as reliable as the equipment coordinating it: the catheter in the heart depends on the box at the bedside to manage its purge, its flow and its alarms. Because the controllers were shipped worldwide, the action reaches cardiac programmes well beyond the United States [s1].

The split between domestic and international units — 3,733 in the United States and 1,499 elsewhere — gives a sense of how concentrated the installed base is, and why a single sensor-assembly fault becomes a global correction rather than a local one [s1]. For a device used episodically, in emergencies and scheduled high-risk cases alike, the practical question is less how many controllers exist than whether a working one is to hand when a patient needs support; that is the continuity a Class I recall of the console puts in play [s1].

What to do

This is a recall aimed squarely at hospitals and the cardiac teams who operate Impella systems, not at patients or the public; the controller is a professional critical-care device [s1][s2]. A Class I recall sets a practical task for those teams: identify whether any affected controllers are in service, follow Abiomed's correction instructions, and keep the manufacturer's guidance on hand for managing a purge-pressure or cassette-recognition alert during use [s1].

For patients and families, the device sits inside intensive care rather than the home, so there is no shelf to check. Reasonable questions for a care team include whether a hospital's Impella controllers are among those named and what the unit's plan is if an alert appears mid-support [s1]. Those conversations belong with the treating clinicians, who can weigh them against an individual patient's situation.

This article describes an FDA enforcement action and is not medical advice. Questions about heart-pump support or any recall affecting a particular course of treatment are for the treating cardiology and critical-care teams, who can check controller product codes against the agency's record.

Sources

• FDA Enforcement Report Z-3148-2026: Abiomed Automated Impella Controller (AIC) — U.S. Food and Drug Administration, report date 23 September 2026
• 510(k) K093801: Impella Controller, Abiomed — U.S. Food and Drug Administration, decision date 8 July 2010